Study of CT071 Injection in RRMM or PPCL

Phase 0 Active not recruiting 20 enrolled Shanghai Changzheng Hospital CARsgen Therapeutics Co., Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

A Clinical Trial to Explore the Safety and Efficacy of CT071 injection in Patients with Relapsed/Refractory Multiple Myeloma or Primary Plasma Cell Leukemia

Timeline

Start: 2023-04-28
Primary completion: 2025-07
Completion: 2025-07

Publications

Jin L, Gu S, Ruan Q, Lu J, Qiang W, He H, Fan X, Liu J, Guo P, Meng X, Rajakumaraswamy N, Chen D, Li Z, Du J. GPRC5D-targeted CAR T-cell therapy (CT071) in patients with relapsed or refractory multiple myeloma: a first-in-human, single-centre, single-arm, phase 1 trial. Lancet Haematol. 2025 Oct;12(10):e798-e807. doi: 10.1016/S2352-3026(25)00176-0.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CT071	Cell therapy	100000 cells/kg	—
Subject	CT071	Cell therapy	300000 cells/kg	—

Study of CT071 Injection in RRMM or PPCL

Summary

Timeline

Publications

Drugs

Indications